The Role of Renal Medullary Bilirubin and Biliverdin Reductase in Angiotensin II-Dependent Hypertension
American Journal of Hypertension · 2025
DOI: 10.1093/ajh/hpae150 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hypertension, 2025. Verfasst von Gertrude Arthur und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Biophysics, Cardiovascular-Renal Research Center, Cardiorenal, and Metabolic Diseases Research Center, University of Mis…. Hauptthemen laut MEDLINE: Angiotensin II, Bilirubin, Hypertension, Oxidoreductases Acting on CH-CH Group Donors. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
BACKGROUND Increased circulating bilirubin attenuates angiotensin (Ang) II-induced hypertension and improves renal hemodynamics. However, the intrarenal mechanisms that mediate these effects are not known. The goal of the present study was to test the hypothesis that bilirubin generation in the renal medulla plays a protective role against Ang II-induced hypertension. METHODS Twenty-week-old male C57Bl/6J mice were implanted with intrarenal medullary interstitial (IRMI) catheters following unilateral nephrectomy. After this time, biliverdin IXα was specifically infused into the kidney (3.6 mg/day) for 3 days before implantation with an osmotic minipump delivering Ang II (1,000 ng/kg/min). BP was recorded for 3 days, 1 week after minipump infusion, in conscious mice. To further explore the antihypertensive role of renal medullary bilirubin generation, mice with specific deletion of biliverdin reductase-A (Blvra) in the thick ascending loop of Henle were generated. At 20 weeks, BlvraTALHKO and control mice (Blvrafl/fl) were infused with Ang II for 2 weeks. RESULTS IRMI infusion of biliverdin significantly decreased blood pressure compared with mice infused with vehicle (118 ± 4 vs. 158 ± 2 mmHg, p < 0.05). Angiotensin-II infusion resulted in significantly higher blood pressure measured in conscious mice 7 days after implantation in BlvraTALHKO as compared to Blvrafl/fl mice (152 ± 2 vs. 140 ± 3 mmHg, P < 0.05). CONCLUSIONS Altogether, these findings show that medullary bilirubin and biliverdin reductase can improve hypertension and that mechanisms that increase bilirubin and biliverdin reductase in the renal medulla could be an effective approach to treat hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Biophysics, Cardiovascular-Renal Research Center, Cardiorenal, and Metabolic Diseases Research Center, University of Mississippi Medical Center, Jackson, MS, USA.
ORCID-Profile: Gertrude Arthur, Heather A Drummond, David E Stec
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Heart, Lung, and Blood Institute
- National Institute of General Medical Sciences
Zitieren
APA
Arthur, G., Wasson, A. R., Straughan, R. E., Drummond, H. A., & Stec, D. E. (2025). The Role of Renal Medullary Bilirubin and Biliverdin Reductase in Angiotensin II-Dependent Hypertension. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpae150
Vancouver
Arthur G, Wasson AR, Straughan RE, Drummond HA, Stec DE. The Role of Renal Medullary Bilirubin and Biliverdin Reductase in Angiotensin II-Dependent Hypertension. American Journal of Hypertension. 2025. doi:10.1093/ajh/hpae150
BibTeX
@article{Arthur2025,
author = {Arthur, Gertrude and Wasson, Andrew R and Straughan, Ross E and Drummond, Heather A and Stec, David E},
title = {The Role of Renal Medullary Bilirubin and Biliverdin Reductase in Angiotensin II-Dependent Hypertension},
journal = {American Journal of Hypertension},
year = {2025},
doi = {10.1093/ajh/hpae150}
}
EUVIMED